{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["28(46)"],"submitter":["Anderle K"],"pubmed_abstract":["<h4>Background</h4>Irritable bowel syndrome (IBS) is a highly prevalent gastrointestinal disorder with poor response to treatment. IBS with predominant diarrhea (IBS-D) is accompanied by abdominal pain as well as high stool frequency and urgency. Purified clinoptilolite-tuff (PCT), which is approved by the Food and Drug Administration for use as a dietary supplement with the brand name G-PUR<sup>®</sup>, has previously shown therapeutic potential in other indications based on its physical adsorption capacity.<h4>Aim</h4>To assess whether symptoms of IBS-D can be ameliorated by oral treatment with PCT.<h4>Methods</h4>In this randomized, placebo-controlled, double-blind pilot study, 30 patients with IBS-D diagnosis based on Rome IV criteria were enrolled. Following a 4-wk run-in phase, 14 pa"],"journal":["World journal of gastroenterology"],"pagination":["6573-6588"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9782844"],"repository":["biostudies-literature"],"pubmed_title":["Safety and efficacy of purified clinoptilolite-tuff treatment in patients with irritable bowel syndrome with diarrhea: Randomized controlled trial."],"pmcid":["PMC9782844"],"pubmed_authors":["Gouya G","Wolzt M","Moser G","Peter J","Freissmuth M","Tschegg C","Meisslitzer C","Anderle K","Keip B"],"additional_accession":[]},"is_claimable":false,"name":"Safety and efficacy of purified clinoptilolite-tuff treatment in patients with irritable bowel syndrome with diarrhea: Randomized controlled trial.","description":"<h4>Background</h4>Irritable bowel syndrome (IBS) is a highly prevalent gastrointestinal disorder with poor response to treatment. IBS with predominant diarrhea (IBS-D) is accompanied by abdominal pain as well as high stool frequency and urgency. Purified clinoptilolite-tuff (PCT), which is approved by the Food and Drug Administration for use as a dietary supplement with the brand name G-PUR<sup>®</sup>, has previously shown therapeutic potential in other indications based on its physical adsorption capacity.<h4>Aim</h4>To assess whether symptoms of IBS-D can be ameliorated by oral treatment with PCT.<h4>Methods</h4>In this randomized, placebo-controlled, double-blind pilot study, 30 patients with IBS-D diagnosis based on Rome IV criteria were enrolled. Following a 4-wk run-in phase, 14 pa","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Dec","modification":"2025-04-21T14:10:43.655Z","creation":"2025-02-19T03:01:33.957Z"},"accession":"S-EPMC9782844","cross_references":{"pubmed":["36569277"],"doi":["10.3748/wjg.v28.i46.6573"]}}